The biologic disease-modifying anti-rheumatic drugs (bDMARDs) etanercept, infliximab, and adalimumab are tumour necrosis factor (TNF) inhibitors for which RA is among their approved indications [11–13]. This evidence concerns the gene TNF and rheumatoid arthritis.